Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Metastatic Breast Cancer Clinical Trial

Official title:

A Randomized, Double-blind, Parallel-group, Comparative Phase I Study to Evaluate the Safety and Pharmacokinetics of Single Intravenous (IV) Administration of GB221 Versus Herceptin® (Trastuzumab)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04175171
• Other study ID #: GB221-001
• Status: Completed
• Phase: Phase 1
• Start date: November 7, 2011
• Est. completion date: March 8, 2012

Study information

• Verified date: November 2019
• Source: Genor Biopharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: March 8, 2012
• Est. primary completion date: January 8, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

To be enrolled in the study, subjects must meet the following criteria

1. Males aged 18 to 45 years.

2. Healthy as judged by medical examination and medical history, and clinical chemistry and hematology screening.

3. Body weight within the normal range for height (BMI between 19.0 and 29.0, inclusive) up to a maximum of 90 kg.

4. Normal or non-clinically significant ECG.

5. Normotensive (systolic: 90 - 140; diastolic: 50 - 90 mm Hg, inclusive) and heart rate (40 -100 bpm, inclusive).

6. Willingness to give written and informed consent prior to any studyrelated procedures being conducted

Exclusion Criteria:

Subjects will be ineligible for the study if any of the following criteria apply:

1. Receipt of any investigational agent or drug within 4 weeks of entry to the study.

2. Use of any medicine - prescription, over-the-counter or herbal - in the 7 days prior to the treatment day and until 12 weeks after the treatment day.

3. Donation of blood (or loss of blood) greater than 400 ml within 3 months of the study.

4. Clinically significant drug allergy or sensitivity to any medication.

5. A history of chronic or recurrent infections.

6. A recent history of surgery.

7. History or presence of malignancy (with the exception of successfully treated basal cell carcinoma).

8. Inability to communicate or cooperate with the Principal Investigator because of English language difficulties or poor mental development.

9. A history (within the last 5 years) or evidence of alcohol or drug abuse (excepting tobacco use less than 10 cigarettes per day).

10. A positive urine test for drugs of abuse or alcohol either at screening or on the day of admittance for drug administration.

11. Vaccination of any type within the previous month.

12. A history of major psychiatric illness (such as bipolar disorder, schizophrenia or persistent major depression). Previous minor depression/adjustment disorder is acceptable if currently asymptomatic.

13. Consumption of more than 3 standard drinks per day, and not able to abstain from alcohol totally within 24 hours of dose administration.

14. Presence of current infection with tuberculosis, Hepatitis B, Hepatitis C or HIV.

15. History of asthma or other chronic respiratory disease in the past 5 years.

16. History of neurological or neuromuscular disease.

17. History of hypertension or cardiovascular disease, including congestive heart failure and cardiomyopathy or a clinically significant echocardiogram finding at the screening visit.

18. History of bladder or urethral disease.

19. Smoking cigarettes > 10 per day.

20. Any other condition which in the view of the Principal Investigator is likely to interfere with the study or put the subject at risk.

Related Conditions & MeSH terms

• Metastatic Breast Cancer

Intervention

Drug:
• Coprelotamab Injection
The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
• Trastuzumab Injection
The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.

Locations

Country	Name	City	State
Australia	Linear Clinical Research Limited	Nedlands	Western Australia

Sponsors (1)

Lead Sponsor	Collaborator
Genor Biopharma Co., Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	physical examination	physical examination	Up to 84 days
Primary	adverse event	adverse event	Up to 84 days
Primary	blood pressure	blood pressure	Up to 84 days
Primary	heart rate	heart rate	Up to 84 days
Primary	respiration rate	respiration rate	Up to 84 days
Primary	oxygen saturation	oxygen saturation	Up to 84 days
Primary	temperature	temperature	Up to 84 days
Secondary	C max	C max	Up to 84 days
Secondary	t max	t max	Up to 84 days
Secondary	AUC	AUC	Up to 84 days
Secondary	CL	CL	Up to 84 days
Secondary	t ½	t ½	Up to 84 days
Secondary	V	V	Up to 84 days